Table 1.

Demographic and pharmacokinetic data of the study population at baseline

	Early (mean±SD)	Delayed (mean±SD)	p-value
Patients assessed on day1:day14	34:31	29:27	–
Age (months)	15.5 (16.3)	14.59 (10.8)	0·57
Sex (M:F)	19:15	17:12	0·52
Edema at admission (N)	5	7	0.65
Rifampicin co-administration (N)	10	10	0·19
Time to ART initiation (days)	6.2	23.7	0·0001
Weight for Age Z-score	−3.6 (1.2)	−3.2 (1.6)	0.12
Weight (kg)	6.5 (2.8)	6.6 (2.6)	0.86
Height (cm)	67.1 (14.6)	67.9 (12.01)	0.82
BMI Z-score	−2.5 (1.8)	−1.8 (2.0)	0.15
Fat free mass (FFM)	5.1 (1.8)	5.5 (1.9)	0.41
Mid-upper arm circumference (cm)	11.1 (1.7)	19.0 (2.3)	0.15
Hemoglobin (g/dL)	8.9 (2.1)	8.8 (1.9)	0.74
Total Protein (g/dL)	65.0 (17.8)	65.2 (16.5)	0.99
Albumin (g/dL)	22.7 (8.0)	21.6 (6.4)	0.34
Creatinine	33.9 (34.2)	35.4 (31.6)	0.87
Cholesterol	2.7 (1.2)	2.9 (1.1)	0.48
Triglyceride	3.2 (2.4)	2.3 (1.5)	0.28

SD: Standard deviation, M: Male, F: Female, N: number, ART: antiretroviral treatment, BMI: Body mass index